Condensed Consolidated Statements of Income (Unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Revenue, net:
Core companion animal health	$ 15,701	$ 14,023	$ 32,281	$ 30,464
Other vaccines, pharmaceuticals and products	2,570	3,424	5,165	6,488
Total revenue, net	18,271	17,447	37,446	36,952
Cost of revenue	10,223	9,978	20,475	21,185
Gross profit	8,048	7,469	16,971	15,767
Operating expenses:
Selling and marketing	4,751	3,570	9,639	7,530
Research and development	203	703	537	1,034
General and administrative	2,711	2,309	5,330	4,776
Total operating expenses	7,665	6,582	15,506	13,340
Operating income (loss)	383	887	1,465	2,427
Interest and other expense, net	(57)	142	85	165
Income (loss) before income taxes	440	745	1,380	2,262
Current tax expense	34	53	82	159
Deferred tax expense (benefit)	144	235	452	730
Total income tax expense (benefit)	178	288	534	889
Net income (loss)	$ 262	$ 457	$ 846	$ 1,373
Basic net income (loss) per share	$ 0.05	$ 0.09	$ 0.16	$ 0.26
Diluted net income (loss) per share	$ 0.05	$ 0.09	$ 0.15	$ 0.26
Weighted average outstanding shares used to compute basic net income (loss) per share	5,327,000	5,234,000	5,296,000	5,233,000
Weighted average outstanding shares used to compute diluted net income (loss) per share	5,583,000	5,353,000	5,517,000	5,298,000